154 related articles for article (PubMed ID: 23110309)
21. What do we do with chronic lymphocytic leukemia with 17p deletion?
Sellner L; Denzinger S; Dietrich S; Glimm H; Merkel O; Dreger P; Zenz T
Curr Hematol Malig Rep; 2013 Mar; 8(1):81-90. PubMed ID: 23188619
[TBL] [Abstract][Full Text] [Related]
22. Frequency Of TP53 Gene Mutation In Patients With Chronic Lymphocytic Leukaemia.
Qadir H; Nasir N; Qadir N; Adil SN; Tanzeem H; Qadir A
J Ayub Med Coll Abbottabad; 2020; 32(4):523-526. PubMed ID: 33225656
[TBL] [Abstract][Full Text] [Related]
23. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
Zenz T; Benner A; Döhner H; Stilgenbauer S
Cell Cycle; 2008 Dec; 7(24):3810-4. PubMed ID: 19098429
[TBL] [Abstract][Full Text] [Related]
24. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
Zenz T; Mohr J; Edelmann J; Sarno A; Hoth P; Heuberger M; Helfrich H; Mertens D; Dohner H; Stilgenbauer S
Leuk Lymphoma; 2009 Mar; 50(3):510-3. PubMed ID: 19347737
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness.
Rossi D; Cerri M; Deambrogi C; Sozzi E; Cresta S; Rasi S; De Paoli L; Spina V; Gattei V; Capello D; Forconi F; Lauria F; Gaidano G
Clin Cancer Res; 2009 Feb; 15(3):995-1004. PubMed ID: 19188171
[TBL] [Abstract][Full Text] [Related]
26. Managing Patients With TP53-Deficient Chronic Lymphocytic Leukemia.
Edelmann J; Gribben JG
J Oncol Pract; 2017 Jun; 13(6):371-377. PubMed ID: 28605616
[TBL] [Abstract][Full Text] [Related]
27. Genomic data in prognostic models-what is lost in translation? The case of deletion 17p and mutant TP53 in chronic lymphocytic leukaemia.
Chin-Yee B; Sadikovic B; Chin-Yee IH
Br J Haematol; 2020 Mar; 188(5):652-660. PubMed ID: 30836431
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
29. TP53 Mutations are infrequent in newly diagnosed chronic lymphocytic leukemia.
Zainuddin N; Murray F; Kanduri M; Gunnarsson R; Smedby KE; Enblad G; Jurlander J; Juliusson G; Rosenquist R
Leuk Res; 2011 Feb; 35(2):272-4. PubMed ID: 20870288
[TBL] [Abstract][Full Text] [Related]
30. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype.
Dicker F; Herholz H; Schnittger S; Nakao A; Patten N; Wu L; Kern W; Haferlach T; Haferlach C
Leukemia; 2009 Jan; 23(1):117-24. PubMed ID: 18843282
[TBL] [Abstract][Full Text] [Related]
31. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.
Pozzo F; Dal Bo M; Peragine N; Bomben R; Zucchetto A; Rossi F; Degan M; Rossi D; Chiarenza A; Grossi A; Di Raimondo F; Zaja F; Pozzato G; Secchiero P; Gaidano G; Del Poeta G; Zauli G; Fo À R; Guarini A; Gattei V
J Hematol Oncol; 2013 Nov; 6():83. PubMed ID: 24283248
[TBL] [Abstract][Full Text] [Related]
32. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.
Mohr J; Helfrich H; Fuge M; Eldering E; Bühler A; Winkler D; Volden M; Kater AP; Mertens D; Te Raa D; Döhner H; Stilgenbauer S; Zenz T
Blood; 2011 Feb; 117(5):1622-32. PubMed ID: 21115975
[TBL] [Abstract][Full Text] [Related]
33. ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia.
Pospisilova S; Gonzalez D; Malcikova J; Trbusek M; Rossi D; Kater AP; Cymbalista F; Eichhorst B; Hallek M; Döhner H; Hillmen P; van Oers M; Gribben J; Ghia P; Montserrat E; Stilgenbauer S; Zenz T;
Leukemia; 2012 Jul; 26(7):1458-61. PubMed ID: 22297721
[TBL] [Abstract][Full Text] [Related]
34. The role of TP53 network in the pathogenesis of chronic lymphocytic leukemia.
Wang C; Wang X
Int J Clin Exp Pathol; 2013; 6(7):1223-9. PubMed ID: 23826404
[TBL] [Abstract][Full Text] [Related]
35. Chronic lymphocytic leukemia with TP53 gene alterations: a detailed clinicopathologic analysis.
Liu YC; Margolskee E; Allan JN; Mathew S; Bhavsar E; Casano J; Orazi A; Furman RR; Geyer JT
Mod Pathol; 2020 Mar; 33(3):344-353. PubMed ID: 31477813
[TBL] [Abstract][Full Text] [Related]
36. Management of high risk chronic lymphocytic leukaemia (CLL) patients in Australia.
Kuss BJ; Tam CS
Intern Med J; 2017 Dec; 47 Suppl 6():5-10. PubMed ID: 29250930
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
[TBL] [Abstract][Full Text] [Related]
38. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL.
Griffin R; Wiedmeier-Nutor JE; Parikh SA; McCabe CE; O'Brien DR; Boddicker NJ; Kleinstern G; Rabe KG; Bruins L; Brown S; Bonolo de Campos C; Ding W; Leis JF; Hampel PJ; Call TG; Van Dyke DL; Kay NE; Cerhan JR; Yan H; Slager SL; Braggio E
Blood Adv; 2023 Jul; 7(13):3169-3179. PubMed ID: 36877634
[TBL] [Abstract][Full Text] [Related]
39. Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanism.
Liu J; Chen G; Pelicano H; Liao J; Huang J; Feng L; Keating MJ; Huang P
Oncotarget; 2016 Nov; 7(44):71378-71389. PubMed ID: 27655686
[TBL] [Abstract][Full Text] [Related]
40. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]